Quality-of-Life Assessment in Rheumatoid Arthritis

被引:0
|
作者
Anthony S. Russell
机构
[1] University of Alberta,Rheumatic Disease Unit, 562 Heritage Medical Research Centre
来源
PharmacoEconomics | 2008年 / 26卷
关键词
Rheumatoid Arthritis; Infliximab; Etanercept; Adalimumab; Abatacept;
D O I
暂无
中图分类号
学科分类号
摘要
Rheumatoid arthritis (RA) is a chronic and lifelong autoimmune disorder that results in significant pain, disability and excess mortality if untreated or inadequately treated. Quality-of-life (QOL) assessments are particularly important in the absence of a cure for RA. Generic and disease-specific patient-reported QOL instruments, such as the Health Assessment Questionnaire (HAQ) Disability Index and the SF-36, have proven validity and sensitivity for assessment of changes in QOL in clinical trials of disease-modifying anti-rheumatic drugs (DMARDs). However, these instruments are rarely utilized in clinical practice, and patients have reported that the actual clinical assessments alone do not address important parameters, such as fatigue and disturbed sleep, which significantly
引用
收藏
页码:831 / 846
页数:15
相关论文
共 50 条